A Multistep Computational Approach to Achieve a Complete Human 5‐Lipoxygenase Structure and Provide a Pharmacophore Model for Further Drug Design

TL;DR

Researchers used computational methods to build a complete structure of 5-lipoxygenase and developed a model to help design new inhibitors for treating diseases like asthma and cancer.

Contribution

The study presents the first full-length open conformation structure of 5-LOX and a pharmacophore model for inhibitor design.

Findings

A full-length open conformation structure of 5-LOX was reconstructed using computational methods.

A pharmacophore model was developed to aid in the rational design of 5-LOX inhibitors.

Dynamic simulations validated the quality of the reconstructed 5-LOX model.

Abstract

Human 5‐lipoxygenase (5‐LOX) plays a crucial role in the biosynthesis of leukotrienes (LTs). Therefore, 5‐LOX inhibitors are designed as effective agents for the treatment of several diseases such as asthma, cardiovascular disorders, allergies, and cancer. Insights into crystal structures of several 5‐LOX isoforms have revealed that this protein adopts two different conformations (open/closed) through modulation of its Hα2 and arched helix regions, which are conditioned by the presence or absence of ligand in the active site; moreover, these structures are incomplete in regions critical for ligand binding. To advance the design of 5‐LOX inhibitors, we developed a computational procedure to reconstruct the first full‐length open conformation structure of 5‐LOX complexed with chelating inhibitor within the active site. Dynamic simulations and protein model validation confirmed the quality of our model, which was subsequently used for docking analyses and culminated in the development of a structure‐based pharmacophore model. These computational studies might constitute powerful tools for rationally designing and identifying novel 5‐LOX iron chelator inhibitors.

Starting from incomplete structural information of 5‐lipoxygenase (5‐LOX), a multistep computational pipeline in silico led to powerful tools for the rational design and identification of novel chelator inhibitors. A reconstruction of the first full‐length 5‐LOX was performed and used to apply docking studies to enable to create a pharmacophore model.© 2026 WILEY‐VCH GmbH

Figures